Are you ready to tackle the biggest trends driving cost in 2026? The next generation of GLP-1s and specialty drugs will treat more indications, have more widespread use, and be even more difficult to manage. In 2026, GLP-1s are expected to receive approval for prediabetes, which could make nearly half the U.S. population eligible. And dozens of new, expensive specialty drugs are expected to hit the market.
The budget challenges will continue to compound. Benefits advisors need to act now to deliver sustainable pharmacy benefits solutions. This guide outlines critical action you can take to:
- Align plan goals to meet clients' business and workforce needs
- Use clinical management to cut waste and optimize outcomes
- Understand what level of transparency your clients have - and need
- Assess if alternate solutions to help members access GLP-1s are right for your clients
- Keep track of – and adapt to – market dynamics